arrow
M

Mansour Alfayez

king faisal specialist hospital
H指数:20
被引数:1,939

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Outcomes of Axicabtagene Ciloleucel CAR-T Therapy in Large B-Cell Lymphoma: A Single-Center Observational Study

大型B细胞淋巴瘤中Axicabtagene Ciloleucel CAR-T疗法的真实世界结局:一项单中心观察性研究

2026-04-050
PRE
Twelve-year utilization and outcomes of haploidentical hematopoietic stem cell transplantation (HSCT) in the Eastern Mediterranean (EM) region: A multicenter EMBMT registry analysis

十二年同种异基因造血干细胞移植(HSCT)在东地中海(EM)地区的应用与结果:一项多中心EMBMT注册分析

2026-04-010
PRE
Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia

患有费城阳性b细胞急性淋巴细胞白血病的青少年和年轻人的移植结果

2026-01-250
PRE
Prognostic Factors and Real-World Outcomes in Adolescents and Young Adults (AYA) With Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL) Treated With the AYA-15 Protocol: A Retrospective Cohort Study From a Tertiary Care Referral Center in the Middle East

预后因素及真实世界结局:一项来自中东一家三级转诊中心的研究,该研究针对接受AYA-15方案治疗、患有费城染色体阴性急性淋巴细胞白血病(ALL)的青少年及年轻成人(AYA)进行回顾性队列研究。

2025-07-170
PRE
Outcomes of Adolescent and Young Adult (AYA) patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Treated with Tisagenlecleucel, real world evidence from the Middle East

中东地区接受Tisagenlecleucel治疗的复发/难治性B细胞急性淋巴细胞白血病青少年和年轻成年(AYA)患者的结局:真实世界证据

2025-07-170
PRE
Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experience

人类白细胞抗原相合同胞移植来自近亲与非近亲父母的结局比较:一项单中心经验

2025-04-290
PRE
Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Patients Receiving Inotuzumab Ozogamicin Followed By Total Body Irradiation-Based Conditioning for Stem Cell Transplantation: A Risk Mitigation Strategy

正弦波形梗阻综合征/静脉闭塞病在接受伊诺妥单抗奥佐米星后接受基于全身照射的预处理进行干细胞移植的患者中的发生率:一种风险缓解策略

BLOOD
IF23.1
2024-11-050
PRE
Non-Western Real-World Experience of Axi-Cel CAR-T in Refractory/Relapsed B-Cell Lymphoma from a Tertiary Center in Saudi Arabia

沙特阿拉伯一家三级中心中,非西方真实世界经验:Axi-Cel CAR-T在难治性/复发性B细胞淋巴瘤中的应用

BLOOD
IF23.1
2024-11-050
PRE
Favorable Outcomes with Bridging Radiation Therapy Prior to Anti-CD19 Chimeric Antigen Receptor T-Cell CART in B Cell Lymphoma, a Report from Saudi Arabia

桥接放射治疗在抗-CD19嵌合抗原受体T细胞(CART)治疗前应用于B细胞淋巴瘤的积极结果:来自沙特阿拉伯的报告

BLOOD
IF23.1
2024-11-050
PRE
Myeloablative Haploidentical Donor Hematopoietic Transplantation Using Post-Transplantation Cyclophosphamide and Antithymocyte Globulin
2024-03-010
PRE
Incidence and risk factors for secondary graft failure in uniformly treated patients with severe aplastic anemia receiving fludarabine and cyclophosphamide for conditioning and matched sibling bone marrow graft as stem cell source
2023-12-010
PRE
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study
CANCER
IF5.1
2022-04-229
OAAI
Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA- Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

在缺乏完全HLA匹配的相关供者的严重再生障碍性贫血患者中,前期替代供者移植与免疫抑制治疗的比较: 代表欧洲血液和骨髓移植小组的严重再生障碍性贫血工作组的回顾性研究的系统评价和荟萃分析

2022-02-0115
OAAI
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML (vol 13, 132, 2020)

AML患者序贯FLT3-inhibitor-based治疗的结果 (第13,132,2020卷)

2021-02-232
OAAI
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
CANCER
IF5.1
2020-10-2910
OAAI